Slingshot members are tracking this event:
European CHMP Adopts Positive Opinion on Gilead’s Type II Variation Application for Truvada for Reducing the Risk of Sexually Acquired HIV
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Jul 22, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Truvada, Sexually Acquired Hiv